Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are b

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and S

NEW YORK--(BUSINESS WIRE)---- $QURE #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds

uniQure N.V. (NASDAQ: QURE - Get Free Report)'s share price was down 5.5% on Tuesday after Barclays

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both heal

Shares of uniQure N.V. (NASDAQ: QURE - Get Free Report) gapped down prior to trading on Monday after

Barclays analyst Eliana Merle downgrades uniQure (NASDAQ:QURE) from Overweight to Equal-Weight an

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and lowers the pr

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors headin

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating po

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month

On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and lowers t

uniQure lost more than a third of its value in a single session after Huntington's data spooked inve

U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result,

uniQure N.V. (QURE) Discusses Additional Data from Phase I/II AMT-130 Study in Huntington's Disease

uniQure NASDAQ: QURE reported updated Phase I/II data for its investigational Huntington's disease g

uniQure N.V. shares plunged over 40% after 48-month AMT-130 data showed reduced disease progression

LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud I

Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's

U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C.

uniQure announced long-term trial results for its Huntington's gene therapy, showing slowed dise

U.S. stocks were mixed; Dow and S&P 500 fell while Nasdaq edged up. Carnival beat estimates. BIO

UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as th

Uniqure stock plummeted Tuesday on a disappointing four-year update for its experimental gene therap

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-mar

UniQure , said ​on Tuesday ‌its Huntington's treatment showed ​44% ​slowing of disease ⁠progression,

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slo

uniQure seeks accelerated FDA approval for its Huntington's gene therapy, AMT-130. William Blair

uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for pa

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's

Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Overweight and raises the pr

Wolfe Research analyst Rudy Li upgrades uniQure (NASDAQ:QURE) from Peer Perform to Outperform and

Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the pr

uniQure (NASDAQ:QURE) reported quarterly losses of $(1.22) per share which missed the analyst consen

Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials,

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure (NASDAQ:QURE) with a Buy an

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

Mizuho analyst Uy Ear maintains uniQure (NASDAQ:QURE) with a Outperform and raises the price targ

Dow Jones index fell 200+ points on Monday. Backblaze Inc rose 30.4% after $335M data storage deal w

uniQure reported early seizure reductions in an AMT-260 epilepsy study, with no treatment-related se

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap

Barclays analyst Eliana Merle upgrades uniQure (NASDAQ:QURE) from Equal-Weight to Overweight and

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and raises t

Leerink Partners analyst Joseph Schwartz maintains uniQure (NASDAQ:QURE) with a Outperform and ra

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:QURE) with a Outperform and raises the pr